Immunological Landscape of HER-2 Positive Breast Cancer

Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo

doi:10.3390/cancers14133167

Cancers (Jun 2022)

Immunological Landscape of HER-2 Positive Breast Cancer

Santiago Moragon,
Cristina Hernando,
Maria Teresa Martinez-Martinez,
Marta Tapia,
Belen Ortega-Morillo,
Ana Lluch,
Begoña Bermejo,
Juan Miguel Cejalvo

Affiliations

Santiago Moragon: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Cristina Hernando: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Maria Teresa Martinez-Martinez: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Marta Tapia: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Belen Ortega-Morillo: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Ana Lluch: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Begoña Bermejo: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain
Juan Miguel Cejalvo: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain

DOI: https://doi.org/10.3390/cancers14133167
Journal volume & issue: Vol. 14, no. 13
p. 3167

Abstract

Read online

Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords